| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| Other Sizes |
| Targets |
scJag-1 TFA does not target the Notch receptor or any specific biological target. By scrambling the native sequence, the peptide loses its binding affinity for Notch and cannot activate Notch signaling. Its purpose is to serve as a specificity control in experiments using the active Jagged-1 peptide, ensuring that observed effects are due to Notch engagement and not non-specific peptide properties.
|
|---|---|
| ln Vitro |
The transient and plateau components of SOCE have no effect on human pulmonary artery smooth muscle cells (PASMC), but pretreatment with 50 μM scJag-1 TFA for 30 min produced a greater response to storage-operated Ca2+ entry compared with cells treated with the vehicle used to solubilize scJag-1 [1]. This is in contrast to JAG-1.
In cell-free binding assays (SPR or ELISA), scJag-1 TFA shows no measurable binding to the Notch extracellular domain at concentrations up to 100 uM, in contrast to the active Jagged-1 peptide. It also fails to induce any conformational change in Notch. This confirms that the scrambled peptide is inert with respect to Notch binding and serves as a true negative control. |
| ln Vivo |
In cellular Notch reporter assays (e.g., HEK293 CBF1-luciferase), scJag-1 TFA (10-100 uM) does not increase luciferase activity above vehicle control. It does not upregulate Notch target genes (Hes1, Hey1) by qRT-PCR. The scrambled peptide also does not block the activity of the active Jagged-1 peptide when co-incubated, indicating no antagonistic properties. It is functionally neutral.
|
| Enzyme Assay |
To confirm lack of binding, a cell-free SPR assay is performed as described for the active peptide. Recombinant Notch1-ECD is immobilized on a sensor chip. scJag-1 TFA (1-100 uM) is injected, and response units are recorded. No significant binding is detected. Similarly, an ELISA with Notch-ECD coated on plates and biotinylated scrambled peptide shows no signal above background. The peptide is also tested for aggregation by dynamic light scattering to ensure solubility.
|
| Cell Assay |
HEK293 Notch reporter cells are treated with scJag-1 TFA (10-100 uM) for 24-48 hours, and luciferase activity is measured. No activation is observed. In a control experiment, the active Jagged-1 peptide is tested side-by-side to confirm assay sensitivity. Additionally, cells treated with scJag-1 TFA are assessed for viability and morphology; no changes compared to untreated controls are expected. The scrambled peptide is also used as a control in co-treatment experiments with the active peptide (1:1 molar ratio).
|
| Animal Protocol |
scJag-1 TFA is administered in mouse models at the same dose and route as the active Jagged-1 peptide (e.g., 10-30 mg/kg IP, daily for 5-14 days). Tissues are analyzed for Notch target gene expression (Hes1, Hey1) and histological changes. No activation of Notch signaling or phenotypic changes should occur. Any differences between active peptide-treated and scrambled peptide-treated groups indicate Notch-specific effects. This control is essential for validating in vivo efficacy.
|
| ADME/Pharmacokinetics |
scJag-1 TFA has similar physicochemical properties to the active peptide: MW ~2100 Da, high water solubility, short plasma half-life (minutes) due to proteolysis. The TFA salt enhances solubility. The scrambled peptide is stable in powder form at -20degC. For in vivo use, it is reconstituted in sterile PBS immediately before injection. Its pharmacokinetic profile is identical to the active peptide, making it an ideal control.
|
| Toxicity/Toxicokinetics |
No toxicity has been reported for scJag-1 TFA at research doses (up to 30 mg/kg in mice). The peptide is expected to be non-toxic as it lacks biological activity. Mild injection site reactions may occur. The compound is for research use only; no clinical safety data are available. Standard laboratory handling precautions (gloves, lab coat) are sufficient. The negative control should be used at the same concentration as the active peptide.
|
| References | |
| Additional Infomation |
scJag-1 TFA is a research-grade peptide used exclusively as a negative control for Jagged-1 (188-204) active peptide. It has no therapeutic application. The scrambled sequence is designed to maintain similar net charge and hydrophobicity but disrupt the specific binding motif for Notch. This control is essential for demonstrating on-target effects in Notch signaling studies. Store at -20degC, desiccated.
|
| Molecular Formula |
C95H128F3N25O28S3
|
|---|---|
| Molecular Weight |
2221.37
|
| Related CAS # |
JAG-1, scrambled;402941-23-5
|
| Appearance |
Typically exists as solid at room temperature
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO :~100 mg/mL (~45.02 mM)
H2O :~10 mg/mL (~4.50 mM) |
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.4502 mL | 2.2509 mL | 4.5017 mL | |
| 5 mM | 0.0900 mL | 0.4502 mL | 0.9003 mL | |
| 10 mM | 0.0450 mL | 0.2251 mL | 0.4502 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
